COMPANY · NIPC 507045491

Teva Pharma – Produtos Farmacêuticos, Lda

This page shows the public contracts the company has signed, which bodies gave them, and who it competed against.

Portal BASE records €304,849,542.08 across 7,486 contracts.

Follow (RSS) · What is RSS?

Identification

Company nameTeva Pharma – Produtos Farmacêuticos, Lda
NIPC507045491
Registered office2740-245 Lisboa
SourceTED (Jornal Oficial da UE), aviso 655857-2026
Record date23 September 2026

Contracted money

Sums of the contract prices on Portal BASE. A contract with several buyers or municipalities counts once in each row, so rows do not add up to the total.

Contracted value by yearBars with the value contracted in each year, from 2012 to 2026. The table below gives the same values.2012: €3,022,454.9720122013: €6,566,524.752014: €36,444,687.7420142015: €45,885,434.042016: €7,869,819.2720162017: €17,199,116.142018: €15,197,099.8420182019: €19,811,009.452020: €15,381,546.7520202021: €18,348,554.082022: €24,349,737.1220222023: €24,154,496.032024: €31,777,588.6620242025: €22,385,091.512026: €16,456,381.732026€45,885,434.04
Contracted value by year
YearContractsContract value
201243€3,022,454.97
201389€6,566,524.75
2014209€36,444,687.74
2015219€45,885,434.04
2016249€7,869,819.27
2017359€17,199,116.14
2018389€15,197,099.84
2019538€19,811,009.45
2020621€15,381,546.75
2021762€18,348,554.08
2022834€24,349,737.12
2023928€24,154,496.03
2024827€31,777,588.66
2025717€22,385,091.51
2026702€16,456,381.73
Contracted value by place of performance
NameContractsContract value
Coimbra354€69,000,984.69
Lisboa1430€40,249,735.17
Setúbal368€38,966,825.69
Faro374€31,894,094.62
Évora195€22,907,584.13
Porto683€17,318,942.99
Almada333€6,438,713.55
Vila Nova de Gaia281€6,049,590.93
Amadora177€3,606,024.99
Leiria203€3,199,589.95
Largest contracts
SubjectYearContract value
Medicamentos do foro oncológico - com base no CPA 2013/62015€31,589,591.37
CPA 2012/6 - Medicamentos do foro oncológico II2014€12,273,247.45
Aquisição de Medicamentos Oncologicos2014€4,443,674.34
41/9035/2024 - 887/2024 - Convite à apresentação de propostas ao abrigo do(s) acordo(s)-quadro 2021/61 - Medicamentos diversos, 2023/304 - Medicamentos do grupo 4: sangue e 2023/491 - Medicamentos do foro oncológico e imunomoduladores para 2024€3,026,044.26
MEDICAMENTOS ANTI-INFECCIOSOS (CP 2012/40 E 41 - SPMS)2014€2,825,565.23

Who they competed with

In 21,123 contracts with a list of competitors, the company took part and was awarded 2,606 (12%).

Companies with the most procedures in common
CompanyProcedures in common
generis1,217
mylan lda1,045
ACCORD HEALTHCARE, UNIPESSOAL, LDA973
sandoz827
farmoz817
hikma lda686
fresenius673
pfizer570
overpharma552
labesfal,, SA498
novartis464
logifarma440
roche farmaceutica quimica383
medinfar382
msd376
glaxo347
Normon, SA330
b.braun medical293
janssen cilag farmaceutica281
pharmakern portugal252
Zentiva, Lda.250
unilfarma226
logista217
medac Sucursal em Portugal199
astrazeneca198
dla sa197
bristol196
tecnimede/Farmoz190
Abbvie. Lda.190
sanofi182

The annual IMPIC file lists competitors for about 42% of contracts. Only these enter the counts, and the award share is measured on them.

Links read in contract documents

Contract documents give addresses and the names of representatives and partners, and Portal BASE and GLEIF give competitors and groups. This is what the records show; the same address or name can have simple explanations.

Links read in contract documents35 companies and 60 links. The list below gives the same content as text.bristol (NIPC 500048193)bristolnovartis (NIPC 500063524)novartissanofi (NIPC 500134960)sanofiglaxo (NIPC 500139962)glaxopfizer (NIPC 500162166)pfizerjanssen cilag … (NIPC 500189412)janssen cilag …msd (NIPC 500191360)msdroche farmaceu… (NIPC 500233810)roche farmaceu…unilfarma (NIPC 500293023)unilfarmamedinfar (NIPC 500384045)medinfarTeva Pharma – Produtos Fa… (NIPC 507045491)Teva Pharma – Produtos Fa…+24 in the list below

Dotted: competed in the same procedure. Dotted: same procedure.

48 more links

Investigations that mention it

No published investigation mentions this company by NIPC.